Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONIC trial of nivolumab after short induction therapy in metastatic triple-negative breast cancer
2015-001969-49Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in triple-negative breast cancer (TNBC) and breast cancer (5 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival. Started Aug 2015; status: active.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2015-001969-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001969-49.